

ACL Laboratories COVID-19 and Influenza Activity Report

Updated: Jul 25, 2021




RESPIRATORY PATHOGEN PANEL 2021

Positivity Rate (%)

MONTH	FLU A	FLU H1 (H1-A)	2009 H1N1 (H1-B)	H3	FLU B	RSV A	RSV B	RSV A/B	PARA 1	PARA 2	PARA 3	Para 4 A	COR 229E	COR NL63	COR OC43	COR HKU1	META	E/R	ADENO	BOCA	LEG	CHL	MYCO
JAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.7	0.3	0.0	0.0	0.0
FEB	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.2	6.1	0.2	0.3	0.0	0.0	0.0
MAR	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.4	0.1	0.1	0.3	0.1	1.4	0.9	0.1	0.4	12.2	1.2	0.3	0.0	0.1	0.1
APR	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.5	0.0	0.0	2.5	2.9	0.0	0.8	15.3	1.4	1.2	0.0	0.0	0.0
MAY	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.7	3.9	0.0	0.2	1.4	3.9	0.0	0.0	14.4	1.7	1.4	0.2	0.0	0.1
JUN	0.0	0.0	0.0	0.0	0.0	0.1	1.8	1.9	0.0	0.3	9.6	0.0	0.3	0.4	2.4	0.0	0.1	15.8	1.1	1.8	0.0	0.0	0.1
JUL	0.0	0.0	0.0	0.0	0.0	1.0	4.7	5.7	0.1	0.3	12.4	0.0	0.1	0.2	1.5	0.0	0.2	15.7	1.5	3.3	0.3	0.0	0.0
AUG																							
SEP																							
OCT																							
NOV																							
DEC																							

Increased prevalence of viruses: **RSV (type B), Parainfluenza 3 and Rhinovirus.**

PARA3 POSITIVITY RATE 2021 (%)



RSV POSITIVITY RATE 2021 (%)

2 SD (+)
2019/2020

9.1

MEAN
2019/2020

2.3

2 SD (-)
2019/20

-4.4


JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC

0.0 0.2 0.3 0.1 0.0 1.9 5.7

ACL RSVAG- Pos rate (%) - Jul 25, 2021

IL % RSVAG


WI % RSVAG



CDC Data RSV pos rate for Region 5 Chicago - (PCR - 14%, Antigen - 14%)


Total PCR Tests

RSV PCR for HHS Region 5 - Chicago (3 week average)



Total Antigen Tests



RSV Antigen for HHS Region 5 - Chicago (3 week average)




SARS-COV-2				Hologic Aptima		Influenza - no activity				RSVAG		
Week	IL % SCVPCR	WI % SCVPCR	IL % COVAG	WI % COVAG	IL % COV19	WI % COV19	IL % FLUPCR	WI % FLUPCR	IL % FLUAG	WI % FLUAG	IL % RSVAG	WI % RSVAG
Jul 25	2.7	4.1	8.0	11.8	2.2	5.1	0	0	0	0	15.5	16.7
Jul 18	1.8	2.6	1.4	7.2	2.1	2.3	0	0	0	0	15.6	21.6
Jul 11	1.6	1.6	1.0	5.0	1.0	1.0	0	0	0	0	16.7	17.4
Jul 4	1.6	1.4	0.0	3.0	1.0	1.4	0	0	0	0	15.5	15.5
Jun 27	1.7	1.5	1.5	2.8	0.3	0.9	0	0	0	0	11.1	8.3
Jun 20	1.5	1.2	1.5	1.1	0.8	0.6	0	0	0	0	7.1	3.2
Jun 13	1.6	1.2	1.4	2.7	1.2	0.7	0	0	0	0	8.6	3.7
Jun 06	2.5	1.6	2.6	2.7	1.2	0.9	0	0	0	0	5.0	0.0
May 29	3.8	2.3	3.1	5.3	1.7	2.1	0	0	0	0	10.7	0.0
May 22	4.5	2.7	3.3	5.7	2.3	3.3	0	0	0	0	0.0	8.7
May 15	5.0	3.4	3.7	6.9	2.7	3.6	0	0	0	0	0.0	0.0

ACL RSVAG Antigen test results are consistent with “atypical” summer RSV outbreak


ACL COVAG and SCVPCR - Pos rate (%) - Jul 25, 2021



Jul 25, 2021 - daily COVID-19 cases in US - CDC



Jul 17, 2021 – SARS-CoV-2 circulating in the US (~83 % Delta variant)



US vaccination status CDC | Data as of: Jul 22, 2021

339,763,765

Vaccines Administered

187,216,168

People who received at least one dose

162,174,165

People who are fully vaccinated*


56.4%

Percentage of the US population that has received at least one dose

48.8%



Percentage of the US population that has been fully vaccinated*

Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, September 27, 2020 – July 17, 2021




2020-21 Influenza Season Week 28 ending Jul 17, 2021

ILI Activity Level




CSF targets positivity rate is 5.6% (VZV and HHV6)

ACL RMEPNL - CSF POSITIVE TARGETS - Jul 25, 2021



The most prevalent GI bacterial targets (Campylobacter)



The most prevalent GI viral targets – Norovirus II – 0.5%

